Personalis, Inc. provided earnings guidance for the full year of 2022. For the year, the company's total company revenue is expected to be in the range of $62.0 million to $67.0 million; Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.0 million to $60.0 million; and Net loss is expected to be in the range of $110.0 million to $115.0 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.365 USD | +2.63% | -7.48% | -35.24% |
05-08 | Transcript : Personalis, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Earnings Flash (PSNL) PERSONALIS Reports Q1 Revenue $19.5M, vs. Street Est of $18.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.24% | 69.08M | |
+46.16% | 56.87B | |
+38.90% | 39.72B | |
-6.53% | 39.27B | |
-4.42% | 28.73B | |
+13.91% | 26.21B | |
-16.91% | 19.79B | |
+31.88% | 12.28B | |
+27.91% | 12.23B | |
+0.29% | 12.12B |
- Stock Market
- Equities
- PSNL Stock
- News Personalis, Inc.
- Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022